Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Enanta Pharmaceuticals Inc’s stock clocked out at $7.9, up 1.94% from its previous closing price of $7.75. In other words, the price has increased by $1.94 from its previous closing price. On the day, 1.49 million shares were traded. ENTA stock price reached its highest trading level at $8.02 during the session, while it also had its lowest trading level at $7.48.
Ratios:
To gain a deeper understanding of ENTA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.00 and its Current Ratio is at 5.00. In the meantime, Its Debt-to-Equity ratio is 2.61 whereas as Long-Term Debt/Eq ratio is at 2.23.
On August 09, 2023, JP Morgan Downgraded its rating to Underweight which previously was Neutral but kept the price unchanged to $14.
Jefferies Downgraded its Buy to Hold on August 08, 2023, whereas the target price for the stock was revised from $49 to $18.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 12 ’25 when Luly Jay R. bought 45,000 shares for $5.69 per share. The transaction valued at 256,050 led to the insider holds 846,638 shares of the business.
Kieffer Tara Lynn sold 2,283 shares of ENTA for $18,401 on Dec 06 ’24. The Chief Product Strategy Officer now owns 29,305 shares after completing the transaction at $8.06 per share. On Dec 06 ’24, another insider, Luu Brendan, who serves as the Chief Business Officer of the company, sold 2,283 shares for $8.06 each. As a result, the insider received 18,401 and left with 36,047 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENTA now has a Market Capitalization of 168885600 and an Enterprise Value of 171872592. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.61 while its Price-to-Book (P/B) ratio in mrq is 2.13. Its current Enterprise Value per Revenue stands at 2.652 whereas that against EBITDA is -1.847.
Stock Price History:
The Beta on a monthly basis for ENTA is 0.81, which has changed by -0.23745173 over the last 52 weeks, in comparison to a change of 0.1529237 over the same period for the S&P500. Over the past 52 weeks, ENTA has reached a high of $13.37, while it has fallen to a 52-week low of $4.09. The 50-Day Moving Average of the stock is -0.45%, while the 200-Day Moving Average is calculated to be 18.68%.
Shares Statistics:
It appears that ENTA traded 184.67K shares on average per day over the past three months and 420360 shares per day over the past ten days. A total of 21.38M shares are outstanding, with a floating share count of 19.97M. Insiders hold about 7.09% of the company’s shares, while institutions hold 86.34% stake in the company. Shares short for ENTA as of 1757894400 were 2848661 with a Short Ratio of 15.43, compared to 1755216000 on 2884903. Therefore, it implies a Short% of Shares Outstanding of 2848661 and a Short% of Float of 14.16.
Earnings Estimates
Enanta Pharmaceuticals Inc (ENTA) is currently under the scrutiny of 5.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$1.02, with high estimates of -$0.93 and low estimates of -$1.11.
Analysts are recommending an EPS of between -$2.39 and -$4.16 for the fiscal current year, implying an average EPS of -$3.72. EPS for the following year is -$3.21, with 6.0 analysts recommending between -$1.97 and -$4.47.
Revenue Estimates
In . The current quarter, 5 analysts expect revenue to total $15.97M. It ranges from a high estimate of $17M to a low estimate of $14.85M. As of . The current estimate, Enanta Pharmaceuticals Inc’s year-ago sales were $14.61MFor the next quarter, 5 analysts are estimating revenue of $16.53M. There is a high estimate of $16.56M for the next quarter, whereas the lowest estimate is $16.5M.
A total of 5 analysts have provided revenue estimates for ENTA’s current fiscal year. The highest revenue estimate was $67.2M, while the lowest revenue estimate was $65.05M, resulting in an average revenue estimate of $66.17M. In the same quarter a year ago, actual revenue was $67.64MBased on 5 analysts’ estimates, the company’s revenue will be $66.2M in the next fiscal year. The high estimate is $71.6M and the low estimate is $58.5M.
